MK-4621
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MK-4621, covering 2022-02-28 to 2022-02-28. Get the full timeline:
Most recent: Clinical Trial Update: Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002) [Phase 1]